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Multiple genetic loci confer susceptibility to breast and ovarian cancers. We have previously developed a model (BOADICEA) under
which susceptibility to breast cancer is explained by mutations in BRCA1 and BRCA2, as well as by the joint multiplicative effects of
many genes (polygenic component). We have now updated BOADICEA using additional family data from two UK population-based
studies of breast cancer and family data from BRCA1 and BRCA2 carriers identified by 22 population-based studies of breast or
ovarian cancer. The combined data set includes 2785 families (301 BRCA1 positive and 236 BRCA2 positive). Incidences were
smoothed using locally weighted regression techniques to avoid large variations between adjacent intervals. A birth cohort effect on
the cancer risks was implemented, whereby each individual was assumed to develop cancer according to calendar period-specific
incidences. The fitted model predicts that the average breast cancer risks in carriers increase in more recent birth cohorts. For
example, the average cumulative breast cancer risk to age 70 years among BRCA1 carriers is 50% for women born in 1920–1929 and
58% among women born after 1950. The model was further extended to take into account the risks of male breast, prostate and
pancreatic cancer, and to allow for the risk of multiple cancers. BOADICEA can be used to predict carrier probabilities and cancer
risks to individuals with any family history, and has been implemented in a user-friendly Web-based program (http://
www.srl.cam.ac.uk/genepi/boadicea/boadicea_home.html).
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The risk of breast cancer in first-degree relatives of women with
breast cancer is approximately two times higher than in women
from the general population (Collaborative Group in Hormonal
Factors in Breast Cancer, 2001). Mutations in the high-risk breast
cancer-susceptibility genes BRCA1 and BRCA2 account for
approximately 15% of this excess familial risk (Easton, 1999; Peto
et al, 1999; Anglian Breast Cancer Study Group, 2000; Dite et al,
2003). We had previously derived a breast cancer susceptibility
model, the Breast and Ovarian Analysis of Disease Incidence and
Carrier Estimation Algorithm (BOADICEA), based on segregation
analysis of breast and ovarian cancer occurrence in a combined
data set, including a population-based series of 1484 breast cancer
cases and 156 multiple case families from the United Kingdom
(Antoniou et al, 2002, 2004). According to this model, genetic
susceptibility to breast cancer is explained by the effects of BRCA1
and BRCA2 mutations, and the residual familial clustering is
explained by the joint multiplicative effect of a large number of
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sgenes each of small effect (i.e., by a polygenic component). Direct
evidence for the polygenic basis of the residual familial clustering
not due to BRCA1 and BRCA2 mutations has more recently been
provided by the identification of further loci that confer moderate
risks, including mutations in CHEK2, ATM, PALB2, BRIP1 (The
CHEK2 Breast Cancer Case–Control Consortium, 2004; Renwick
et al, 2006; Seal et al, 2006; Rahman et al, 2007) and the low-risk
variants identified through genome-wide or candidate gene
association studies (Cox et al, 2007; Easton et al, 2007; Hunter
et al, 2007; Stacey et al, 2007).
The BOADICEA model can be used to estimate the likelihood of
carrying a BRCA1 or a BRCA2 mutation, and the risks of
developing breast or ovarian cancer. However, there are a number
of limitations associated with the first version of BOADICEA. The
model assumed that a fixed set of calendar period incidences
applied to all cohorts, when breast cancer incidences have been
increasing over time (Office for National Statistics, 2001;
Tryggvadottir et al, 2006). Moreover, the incidences were assumed
to change in 5-year intervals when in reality they change smoothly
with age. As part of the model-fitting process, we also estimated
the BRCA1 and BRCA2 breast and ovarian cancer risks, but these
were based on a relatively small number of mutation-carrying
families and were therefore imprecise (Antoniou et al, 2002, 2004).
Finally, the model took into account only the occurrence of a
first breast or a first ovarian cancer and the risks of second or
subsequent cancers were ignored. BRCA1 and BRCA2 mutations
are associated with increased risk of cancer at several sites other
than female breast and ovary. The strongest evidence is for
prostate and pancreatic cancer in BRCA2 carriers, which has been
consistently found in multiple studies (The Breast Cancer Linkage
Consortium, 1999; Tulinius et al, 2002; Edwards et al, 2003;
Kirchhoff et al, 2004; van Asperen et al, 2005; Risch et al, 2006;
Tryggvadottir et al, 2007). There is also more limited evidence for
an increased risk of cancer of the gall bladder, bile duct, stomach
and malignant melanoma (The Breast Cancer Linkage Consortium,
1999; Edwards et al, 2003; Kirchhoff et al, 2004; van Asperen et al,
2005; Risch et al, 2006). BRCA1 carriers have been found to have
elevated risks of colorectal, pancreatic, prostate, testicular and
uterine cancer (Ford et al, 1994; Brose et al, 2002; Thompson and
Easton, 2002; Risch et al, 2006). The colorectal cancer risk,
however, has not been consistently replicated, while the prostate
and pancreatic cancer risks are lower than in BRCA2 carriers. In
addition, male BRCA1 and (to a greater extent) BRCA2 carriers are
at an increased risk of developing breast cancer (Thorlacius et al,
1997; Thompson and Easton, 2001; Risch et al, 2006; Tai et al,
2007), (DF Easton, unpublished data). Incorporation of these
additional cancer phenotypes into the model should provide
greater discrimination between BRCA1 and BRCA2 mutation
carriers and noncarriers.
In this paper, we have attempted to improve BOADICEA by
analysing additional population-based data and by extending the
model to account for the risk of cancer after the first diagnosis and
the risks of cancer at sites other than breast and ovary.
MATERIALS AND METHODS
We combined the data from the two studies used in the initial
model development with data from three additional published
population-based studies. Specifically, the present analysis in-
cludes the following data sets:
(a) The Anglian Breast Cancer Study (ABC, now SEARCH). The
families were identified through 1484 women with breast cancer
diagnosed before the age of 55 years and registered in the East
Anglian Cancer Registry between 1991 and 1996. These index cases
were invited to provide blood samples and complete an
epidemiological questionnaire, including family history of cancer
in all first-degree relatives. The blood samples were tested for
germline mutations in BRCA1 and BRCA2 using conformation-
sensitive gel electrophoresis (CSGE). Mutations were confirmed by
sequencing. These data were used in the initial model development
and the study is described in more detail elsewhere (Anglian Breast
Cancer Study Group, 2000; Antoniou et al, 2001).
(b) UK National Case–Control Study (UK). Women with breast
cancer were identified through two UK population-based case–
control studies. The first study involved 755 patients diagnosed
under the age of 36 years and registered between 1982 and 1985.
The second study included 644 patients diagnosed from age 36 to
45 years and registered between 1988 and 1989. These index cases
provided family history information of breast and ovarian cancer
and were later contacted to provide blood samples. DNA was
screened for germline mutations in BRCA1 and BRCA2 by
heteroduplex analysis. Again, mutations were confirmed by
sequencing. In all, 617 samples were tested for BRCA1 and BRCA2
mutations and were included in our analysis. This data set is
described in detail elsewhere (Peto et al, 1999).
(c) The Manchester Study. Women diagnosed with breast cancer
at or before the age of 30 years were recruited via the North West
Regional Cancer Registry (UK) between 1980 and 1997. A total of
99 index cases provided blood samples, which were screened for
mutations in BRCA1 and BRCA2 using a combination of the
Protein truncation test, single-strand conformation polymorphism/
heteroduplex analysis and fluorescent chemical cleavage of
mismatch analysis. Three-generational pedigrees were constructed
through interviews and were augmented with data from hospital
notes. The study is described in Lalloo et al (2003).
(d) Multiple case families: ‘British’ (B) families. In all, 156
families were ascertained in response to national publicity in the
United Kingdom and by referral by oncologists or general
practitioners. Eligibility was restricted to families with at least
two breast cancer cases, one or more diagnosed before the age of
50 years. Occurrence of cancer and follow-up was recorded on all
family members. One or more individuals from each family
provided blood samples, which were analysed for BRCA1 and
BRCA2 mutations using CSGE (Antoniou et al, 2002). This set of
families was also used in the initial development of BOADICEA.
(e) Meta-analysis families (BRCA families). This data set
included pedigree data from BRCA1 and BRCA2 mutation carriers
identified in 22 population-based studies of breast or ovarian
cancer patients reported by Antoniou et al (2003). A study was
eligible for the meta-analysis if it was based on mutation testing of
a series of index cases diagnosed with either breast (male or
female) or epithelial ovarian cancer and who were unselected for
family history of cancer. In each study, the index cases had to be
tested for BRCA1 and/or BRCA2 mutations by systematic screen-
ing, and family history information had to be available on all
first-degree relatives of identified mutation carriers. To avoid
replication, the families of mutation carriers identified through the
ABC, UK and Manchester studies were not considered to be part of
the BRCA families for the present analysis. A total of 429 families
of BRCA1 and BRCA2 mutation carriers were included in the
present analysis.
BRCA1 and BRCA2 mutations were considered to be disease
causing if they were classified pathogenic according to the
generally accepted criteria (http://research.nhgri.nih.gov/projects/
bic/). For consistency across the population-based studies (ABC,
United Kingdom, Manchester and BRCA), family history informa-
tion was restricted to the first-degree relatives of the index cases.
Segregation analysis
Model fitting was performed using complex segregation analysis of
breast and ovarian cancer occurrences in the combined set of
families described above. Individuals were followed from birth and
were censored at the age of cancer occurrence, age at death or at
the age of 70 years whichever occurred first. Female patients with
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female patients in the combined data set).
In the initial development of BOADICEA, a number of different
genetic models were investigated for the genetic susceptibility to
breast cancer (Antoniou et al, 2002). It was found that the most
parsimonious model was one that incorporated the simultaneous
effects of BRCA1, BRCA2 and a polygenic component representing
the combined multiplicative effect of multiple loci of small effect.
This model is consistent with the recent discovery of multiple low-
risk susceptibility genes (and the failure to identify any further
‘high-risk’ loci by linkage) (Smith et al, 2006; Easton et al, 2007;
Hunter et al, 2007; Stacey et al, 2007). Although it is likely that the
genetic causes of breast cancer are more complicated, for the
present analysis we focused only on polygenic models for the
residual familial clustering of breast cancer other than that due to
mutations in BRCA1 and BRCA2.
The breast cancer incidence for individual i at age t was assumed
to be birth cohort specific, and to depend on the underlying
BRCA1 or BRCA2 genotype and polygenotype through a model of
the form li(t)¼l0(t)exp(Gi(t)þPi(t)), where l0(t) is the baseline
incidence for the cohort, Gi(t) represents the major gene effect at
age t (BRCA1 carrier, BRCA2 carrier or noncarrier) and Pi(t) is the
polygenic effect assumed to be normally distributed with mean
zero and variance s
2(t). The polygenic component was approxi-
mated by the hypergeometric polygenic model (Antoniou et al,
2001; Lange, 2002). More details about the implementation of this
approximation in MENDEL can be found in Antoniou et al (2001).
Under the above model, the polygenotype is assumed to modify
the disease risk in BRCA1 and BRCA2 carriers. In this context, that
is, when Pi(t) acts on BRCA1 and BRCA2 background, the
polygenic component is referred to as the ‘modifying’ component.
In this analysis, we generalised the model to allow for different
polygenic and modifying variances in mutation carriers and
noncarriers. We also fitted models in which the polygenic and
modifying variance was age dependent.
Calendar period- and cohort-specific incidences
The breast and ovarian cancer incidences were assumed to be
calendar period and cohort specific, based on the incidences for
England and Wales (Cancer in five continents volumes I–VIII,
Doll et al, 1966, 1970; Waterhouse et al, 1976, 1982; Muir et al,
1987; Parkin et al, 1992, 2002). Five birth cohorts were assumed for
this purpose (o1920, 1920–1929, 1930–1939, 1940–1949, and
1950 or after), and the incidences were derived by assuming that
the female patient was born at the midpoint of the relevant birth
cohort (1915 for the first cohort and 1955 for the last cohort). The
overall incidences were constrained to agree with the population
incidences for each cohort separately (Antoniou et al, 2001). The
rate ratios associated with the major gene and polygenic effects
(Gi(t), Pi(t)) were assumed not to vary by birth cohort. Owing to
this constraint, the estimated incidences for BRCA1 and BRCA2
carriers and noncarriers were themselves cohort specific.
Incidence smoothing
Published incidences are reported in 5-year intervals, which can
result in large variations in the incidences between adjacent age
intervals. This is particularly an issue for BRCA1 and BRCA2
carriers for whom incidence increases rapidly with age. Since it is
more plausible to assume that incidences vary continuously with
age, we smoothed the population incidences using locally weighted
regression techniques (Royston, 1991). This method was chosen
because it follows the ‘locality’ of the data as opposed to
polynomial smoothing, which is a global graduation technique,
is influenced by the extreme points (young and old ages) and is not
as flexible. Smoothing was carried out using the statistical software
Stata (Stata Corporation, College Station, Texas, USA). The
method involves running a regression at each age ti, using the
data for age ti and a small amount of data near ti. The proportion
of data (bandwidth) used in the regression specifies the degree of
smoothness. Various degrees of smoothness were investigated and
the resulting set of incidences was compared with the original set
of incidences for adherence. As a smoothness criterion, we used
the sum of the absolute values of the third-order finite differences
of the smoothed incidences:
X
t
jD
3^ lðtÞj ð Þ
where
D
klðtÞ¼D
k 1lðt þ 1Þ D
k 1lðtÞ for k ¼ 1;2;...
D
0lðtÞ¼lðtÞ
Smaller values of the sum ( ) correspond to smoother incidence
curves. Consistency of the model with the data was assessed using
a w
2 test statistic, treating the smoothed incidences as expected
values. However, formal tests of significance were not performed
because of the difficulty in determining the correct number of
degrees of freedom for the test.
BRCA1 and BRCA2 relative risks
Two types of models were assumed for the BRCA1 and BRCA2 log-
relative risks (Gi(t)) for both breast and ovarian cancer. Our
primary analysis involved fitting models in which the relative risks
are assumed to be constant within each decade of age (20–29,
30–39, 40–49, 50–59 and 60–69 years). Once the most
parsimonious model for the form of the polygenic and modifying
variance was chosen, we fitted additional models in which the
log-relative hazards were piecewise linear functions of age (see
Appendix), so that the resulting BRCA1 and BRCA2 incidences
were continuous functions of age.
Adjustment for ascertainment
For the ABC, UK and Manchester families, we adjusted for
ascertainment by maximising the conditional likelihood of
observing the phenotypes and genotypes in the families, given
the disease status and age at diagnosis of the index case. For the
BRCA1- and BRCA2-positive families, we maximised the condi-
tional likelihood of observing the disease phenotypes and
genotypes in the family, given the disease status, age at diagnosis
and mutation status of the index case. Since the ‘B’ families were
identified through multiple-affected individuals, we maximised the
likelihood of all phenotypes and genotypes in the family
conditional on all the phenotypic information for the family.
Sensitivity of the mutation testing
To allow for the fact that not all mutations could be detected by the
screening methods used, we allowed in our analysis for a
sensitivity of mutation testing parameter, giving the probability
of detecting a mutation if one exists. We assumed that 70 and 80%,
respectively, of the disease-causing mutations in BRCA1 and
BRCA2 could be detected by the methods used. The sensitivity
parameter only applied for the first screened individual from each
family (the index cases). Variants of uncertain significance (VUSs)
were assumed to be equivalent to a BRCA1- and BRCA2-negative
test, since this is how they are treated in clinical genetics and in
analyses testing the goodness of fit of the model. Although some
such variants may be pathogenic, this effect is allowed for in the
model by the mutation sensitivity parameter (i.e., the incomplete
sensitivity is partly due to pathogenic mutations classified as
VUSs). For the relatives of index patients who were screened for
family-specific mutations, we assumed that the test was 100%
sensitive.
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Nested models were compared against each other using the
likelihood ratio test. The Akaike Information Criterion (AIC) was
used to compare non-nested models (Akaike, 1974).
Parameter estimation
The models were parameterised in terms of the polygenic and
modifying variances, the BRCA1 and BRCA2 allele frequencies in
the population and the natural logarithm of the ratios of the breast
and ovarian cancer incidences in BRCA1 and BRCA2 mutation
carriers to the population incidences (relative hazards). Parameters
were estimated by maximum likelihood, and their variances were
obtained from the observed information matrix. To obtain
confidence intervals for parameters with restricted ranges (e.g.,
allele frequencies) we used transformations to obtain parameters that
are likely to be more normally distributed (Antoniou et al, 2001).
RESULTS
Table 1 summarises the total number of families by the mutation
status of the index case. In all, 2785 families were included in the
analysis, of which 301 were BRCA1 positive and 236 were BRCA2
positive. Table 2 shows the number of breast and ovarian cancer
patients by age at diagnosis for the relatives of the index cases.
The smoothed incidences used in the segregation analyses were
based on a bandwidth of 0.2. This value provided a compromise
between smoothness and adherence to the original published
incidences (data not shown). The graduated calendar- and cohort-
specific incidences included the age-specific features for all cohorts
observed in the general population (data not shown) (Office for
National Statistics, 2001). On the basis of the graduated incidences,
the risk of breast cancer in the general population by the age of 80
years is 8.9, 9.8, 10.4, 10.9 and 11.0% for female patients born prior
to 1920, between 1920–1929, 1930–1939, 1940–1949, and 1950
and after, respectively.
We first fitted three models, with different assumptions about
the polygenic and modifying variances (Table 3). For these models,
the BRCA1 and BRCA2 relative hazards were assumed to be
constant within each 10-year interval: 20–29, 30–39, 40–49, 50–
59 and 60–69 years. In the first model, the polygenic and
modifying variances were constrained to be equal. In the second
model, the polygenic variance was allowed to be different from the
modifying variance, but the latter was constrained to be the same
for BRCA1 and BRCA2 carriers. In the third model, the polygenic
variance and the BRCA1 and BRCA2 modifying variances were all
allowed to vary. In each of these models, the polygenic and
modifying variance were assumed to be constant with age. We
found no evidence that the BRCA1- and BRCA2-modifying
variances were different from each other (P¼0.76). The modifying
variance was estimated to be somewhat lower than the polygenic
variance (1.55 vs 2.02), but the difference was not significant
(P¼0.63). When a single polygenic/modifying variance was
assumed, it was estimated to be 1.99 (95% CI: 1.54–2.57). This
model had the lowest AIC value of the three models (7948.284).
The BRCA1 and BRCA2 parameter estimates for this model are
given in Table 4.
We then fitted three further models, for which the polygenic
variance was allowed to vary by age group (20–29, 30–39, 40–49,
50–59 and 60–69 years; Table 3). When the modifying variance
was restricted to be equal to the polygenic variance, this model did
not fit significantly better than the model with the same constant
polygenic and modifying variance (P¼0.30). The other two
models assumed separate constant modifying variances, which were
either constrained to be equal or different among BRCA1 and
BRCA2 mutation carriers. These models also did not improve the fit
significantly, compared with the model with a constant polygenic/
modifying variance (P¼0.53 and 0.65). The latter two models
assumed constant modifying variances because models with varying
modifying variances resulted in unbounded estimates.
Despite the lack of a significant improvement in fit, the
parameter estimates suggest that the polygenic variance may
decrease with age. We explicitly allowed for this hypothesis by
fitting a model in which the polygenic and modifying variances
were the same linear function of age, that is, sp
2(t)¼sm
2 (t)¼aþbt,
where t represents the age in years, and estimated the parameters a
(¼4.86, 95% CI: 1.8–7.9) and b (¼ 0.06, 95% CI:  0.12 to
 0.0002). Compared with the model with a constant variance,
there was some marginal evidence that this model fitted better
(P¼0.049).
To investigate further the properties of these models, we
computed the age-specific familial relative risks (FRRs) for an
individual with an affected mother predicted by these two models
as described elsewhere (Antoniou et al, 2004). We then contrasted
these against the observed FRR estimated by epidemiological
studies (Collaborative Group in Hormonal Factors in Breast
Cancer, 2001). The predicted FRRs were closer to the observed
values for the model with a polygenic/modifying variance that
decreased with age than the model with a constant variance
(Table 5). When a constant polygenic variance was assumed, the
predicted FRRs decreased markedly at young ages in line with the
observed values, but were still high at ages 55 years and older. The
model with a linearly decreasing polygenic variance predicted an
FRR, which was close to the observed values at all ages.
BRCA1 and BRCA2 incidence smoothing
The model with a linearly decreasing polygenic/modifying variance
was extended to allow for the BRCA1 and BRCA2 log-relative
hazards to be piecewise linear functions of age (see Materials and
Methods, Appendix and Table 6). The allele frequencies of BRCA1
and BRCA2 mutations in the general population were estimated to
be 0.06% (95% CI: 0.04–0.10%) and 0.10% (95% CI: 0.07–0.16%),
respectively. These correspond to population carrier frequencies of
Table 1 Number of families included in the analysis by the mutation
status of the index cases
Study BRCA1 carriers BRCA2 carriers Noncarriers Total
ABC 8 15 1461 1484
UK 16 14 587 617
Manchester 9 7 83 99
B families 21 18 117 156
BRCA 247 182 NA 429
Total 301 236 2248 2785
NA¼not applicable.
Table 2 Number of breast and ovarian cancer cases among the relatives
of index cases, by the age at diagnosis and the mutation status of the index
case
BRCA1 carriers BRCA2 carriers Noncarriers
Age group (years) BC OC BC OC BC OC
o2 0 00000 0
2 0 – 2 9 67507 4
30–39 58 25 34 0 79 2
40–49 84 10 55 2 180 10
50–59 36 9 46 13 135 12
60–69 19 9 28 3 96 5
70+ 12 3 20 4 78 12
BC¼breast cancer; OC¼ovarian cancer.
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risks of breast and ovarian cancer in BRCA1 and BRCA2 mutation
carriers based on this model are shown in Figures 1–4. The
average cumulative risk of breast cancer in BRCA1 carriers over all
possible modifiers was estimated to be 46% by the age of 70 years
for women born before 1920, rising to 59% for women born after
1950. On the basis of the 5th and 95th percentiles of the
distribution of the polygenic/modifying component, the estimated
cumulative breast cancer risks were 7.2 and 98%, respectively, for
carriers born before 1920, rising to 12.0 and 99.9% for carriers
born after 1950. The average cumulative risks of breast cancer in
BRCA2 mutation carriers by the age of 70 years were estimated to
be lower, 39% for women born before 1920 (6.3 and 93% at the 5th
and 95th percentiles, respectively) rising to 51% for those born
after 1950 (9.8 and 98.7% at the 5th and 95th percentiles,
respectively). The estimated ovarian cancer risks were highest
Table 3 Segregation analysis models fitted for the polygenic and modifying variances
Model Age (years) rp
2(t) (95% Cl) rm1
2(t) (95% Cl) rm2
2(t) (95% Cl) Log-lik
sp
2¼sm
2 20–69 1.99 (1.5–2.6) 1.99 (1.5–2.6) 1.99 (1.5–2.6)  3951.142
sp
2, sm
2 20–69 2.02 (1.6–2.6) 1.55 (0.6–4.4) 1.55 (0.6–4.4)  3951.023
sp
2, sm1
2, sm2
2 20–69 2.02 (1.6–2.6) 1.29 (0.3–6.4) 1.68 (1.5–5.5)  3950.978
sp
2(t)¼sm
2(t) 20–29 3.50 (0.8–15.8) 3.50 (0.8–15.8) 3.50 (0.8–15.8)  3948.721
30–39 1.64 (0.8–3.6) 1.64 (0.8–3.6) 1.64 (0.8–3.6)
40–49 2.80 (1.8–4.5) 2.80 (1.8–4.5) 2.80 (1.8–4.5)
50–59 1.83 (1.0–3.4) 1.83 (1.0–3.4) 1.83 (1.0–3.4)
60–69 0.72 (0.2–2.6) 0.72 (0.2–2.6) 0.72 (0.2–2.6)
sp
2(t), sm
2 20–29 3.59 (0.5–25.9) 1.59 (0.6–4.4) 1.59 (0.6–4.4)  3949.089
30–39 2.20 (1.0–4.9) 1.59 (0.6–4.4) 1.59 (0.6–4.4)
40–49 2.71 (1.7–4.3) 1.59 (0.6–4.4) 1.59 (0.6–4.4)
50–59 1.61 (0.8–3.1) 1.59 (0.6–4.4) 1.59 (0.6–4.4)
60–69 0.86 (0.2–3.2) 1.59 (0.6–4.4) 1.59 (0.6–4.4)
sp
2(t), sm1
2, sm2
2 20–29 3.64 (0.5–26.9) 1.32 (0.3–6.2) 1.73 (0.6–5.4)  3949.043
30–39 2.19 (1.0–4.9) 1.32 (0.3–6.2) 1.73 (0.6–5.4)
40–49 2.71 (1.7–4.3) 1.32 (0.3–6.2) 1.73 (0.6–5.4)
50–59 1.61 (0.8–3.1) 1.32 (0.3–6.2) 1.73 (0.6–5.4)
60–69 0.87 (0.2–3.2) 1.32 (0.3–6.2) 1.73 (0.6–5.4)
sp
2(t)¼polygenic variance; sm
2(t)¼modifying variance; sm1
2¼BRCA1 modifying variance; sm2
2¼BRCA2 modifying variance; Log-lik¼log likelihood.
Table 4 Estimated BRCA1 and BRCA2 allele frequencies and relative hazards for model sp
2¼sm
2 in Table 3
BRCA1 BRCA2
Age (years) Frequency (95% Cl) BC RH (95% Cl) OC RH (95% Cl) Frequency (95% Cl) BC RH (95% Cl) OC RH (95% Cl)
0.0006 (0.04–0.10%) 0.0010 (0.06–0.15%)
20–29 44.9 (25.4–79.2) 1.0 21.1 (10.9–40.6) 1.0
30–39 26.2 (18.3–37.3) 39.0 (17.2–88.5) 14.8 (10.2–21.4) 1.0
40–49 19.9 (14.3–27.7) 68.4 (43.5–107.5) 11.0 (7.8–15.5) 3.9 (0.8–19.4)
50–59 9.6 (5.8–15.9) 26.2 (13.6–50.2) 9.7 (6.3–14.7) 19.4 (10.4–36.3)
60–69 8.3 (4.0–17.3) 37.8 (17.8–80.2) 9.1 (5.1–16.1) 7.1 (1.8–28.3)
BC¼breast cancer; OC¼ovarian cancer; RH¼relative hazard. RH are estimated relative to the cohort-specific population incidences. RH assumed to be constant across birth
cohorts.
Table 5 Age-specific observed (Collaborative Group in Hormonal Factors in Breast Cancer, 2001) and predicted FRRs of breast cancer associated with
having an affected mother
Predicted FRR
Age (years) rp
2¼rm
2a
rp
2(t)¼rm
2(t)¼a+bt rp
2(t)¼rm
2(t)¼a+bt
b Observed FRR (95% Cl)
25 5.3 6.7 6.0
30 3.1 3.9 5.8 5.7 (2.7–11.8)
35 2.9 3.4 3.5
40 2.4 2.6 2.6
45 2.2 2.3 2.2 2.0 (1.5–2.8)
50 2.0 1.9 1.9
55 1.9 1.7 1.7 1.6 (1.2–2.1)
60 1.8 1.5 1.5
65 1.7 1.4 1.4 1.4 (1.2–1.7)
70 1.7 1.3 1.3
FRR¼familial relative risk.
aThese models refer to the models in Table 3. BRCA1/2 log-relative hazards assumed to be constant in each decade of age.
bBRCA1/2 log-relative
hazards assumed to be piecewise linear functions of age.
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sfor women born between 1930 and 1939, but the variation across
the birth cohorts was smaller than for breast cancer. For BRCA1
mutation carriers, the ovarian cancer risk by the age of 70 years
was estimated to be 33% for women born prior to 1920, rising to
36% for those born between 1920 and 1939, and then dropping to
34%. For BRCA2 mutation carriers, the corresponding risks were
estimated to be 11, 12 and 11%, respectively. The predicted age-
specific FRRs under this model are shown in Table 5. These are
generally similar to those generated using piecewise constant
hazard ratios, but slightly closer to the observed values.
Risks of cancers at other sites and risks of second cancers
Since reliable data on these additional cancer types were not
available in the main data set used to derive BOADICEA, we used
instead estimated risks derived from the largest published studies
Table 6 Parameter estimates for the final model
Parameter BRCA1 BRCA2 Noncarriers
Allele frequency (95% Cl) 0.0006 (0.04–0.10%) 0.0010 (0.07–0.16%) NA
Average penetrance (%) by the age of 70 years, by the year of birth
Breast cancer Ovarian cancer Breast cancer Ovarian cancer Breast cancer Ovarian cancer
o1920 46 33 39 11 4.5 1.0
1920–1929 51 36 44 11 5.2 1.1
1930–1939 55 36 47 12 5.9 1.1
1940–1949 58 34 50 11 6.4 1.1
1950+ 59 34 51 11 6.5 1.1
Polygenic modifying variance: sp
2(t)¼sm
2(t)¼a+bt
^ a¼4.83 (95% Cl: 1.8–7.9) ^ b¼ 0.06 (95% Cl:  0.12 to 0.00)
NA¼not available. Polygenic/modifying variance is a linear function of age, and the log
BRCA1 and BRCA2 relative hazards are piecewise linear functions of age.
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Figure 1 Average cumulative breast cancer risks for BRCA1 mutation
carriers by birth cohort assumed in BOADICEA.
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Figure 2 Average cumulative ovarian cancer risks for BRCA1 mutation
carriers by birth cohort assumed in BOADICEA.
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Figure 3 Average cumulative breast cancer risks for BRCA2 mutation
carriers by birth cohort assumed in BOADICEA.
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Figure 4 Average cumulative ovarian cancer risks for BRCA2 mutation
carriers by birth cohort assumed in BOADICEA.
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s(see Table 7). We incorporated only prostate and pancreatic
cancer, and male breast cancer, for which the evidence for
association and estimates of risk were most reliable. We assumed
that conditional on the genotype, the age-specific probability of
developing a particular cancer was independent of the probability
of developing any other type of cancer. The incidences of prostate
and pancreatic cancer for BRCA1 and BRCA2 mutation carriers
were obtained by multiplying the cohort and calendar period age-
specific incidence rates from the general population. Noncarriers
were assumed to develop these cancers according to the population
incidences.
The risk of breast cancer in female first-degree relatives of male
breast cancer patients has been estimated to be 2.4 times greater
than the risk in the general population (Basham et al, 2002),
consistent with a common genetic susceptibility to male and
female breast cancer. However, BRCA1 and BRCA2 alone cannot
explain all the observed FRRs (Basham et al, 2002). To allow for
this residual effect, we assumed that the polygenic component in
the model also applied to male patients. The male breast cancer
polygenic variance was chosen such that the predicted FRR to
daughters of male breast cancer patients was equal to 2.4. In
choosing this, the overall male breast cancer incidences over the
BRCA1, BRCA2 (Table 7) and polygenic effects were constrained to
agree with the population incidences. On the basis of this
approach, the male breast cancer polygenic variance was chosen
to be 1.96, close to that estimated for female patients at young ages.
We have also extended the model to allow for the risks of other
cancers after the first cancer diagnosis, including the risk of
contralateral breast cancer. We assumed that the increased risk of
contralateral breast cancer, or of any other cancer after the first
diagnosis (relative to the population rates), was entirely due to the
susceptibility as defined by the model (i.e., no additional variation
in risk). On the basis of this assumption, the contralateral breast
cancer incidence after the first breast cancer, given the genotype, is
half the breast incidence assumed in the standard model (since
only one breast is at risk). Similarly, the incidence of a cancer at
another site, after a first cancer diagnosis, was assumed to be the
same as if the preceding cancer had not occurred, consistent with
the assumption that the site-specific cancer risks are independent
conditional on the genotype. The transition model for female
patients in this extended BOADICEA model is depicted in Figure 5.
A similar model applies to male patients (including prostate cancer
but excluding ovarian cancer).
DISCUSSION
In this report, we have updated and extended our previously
published model BOADICEA using additional data. There are
several additional features in the updated model. The breast and
ovarian cancer incidences in BRCA1 and BRCA2 mutation carriers
are now based on a much larger number of mutation-carrying
families and are, therefore, more reliable; the variance of the
polygenic component is now age dependent as opposed to
constant; and the incidences vary gradually with age and are
cohort and calendar period specific. In addition, the model has
been extended to allow for the risks of male breast, prostate and
pancreatic cancer, and the risks of other cancers after a first
diagnosis.
We have shown that the updated version, with a polygenic
variance that decreases linearly with age, predicts accurately the
FRR of breast cancer observed in epidemiological studies
(Collaborative Group in Hormonal Factors in Breast Cancer,
2001). Such a model is consistent with the hypothesis that a large
number of variants increase the rate at which key mutational
events occur, and the increased relative risk conferred by at least
some variants is higher at younger ages. Direct evidence for a
polygenic component is provided by the recent identification of at
least seven common variants through genome-wide association
and candidate gene studies (Cox et al, 2007; Easton et al, 2007;
Hunter et al, 2007; Stacey et al, 2007). For the two strongest
associations identified by Easton et al (2007) (FGFR2 and TNRC9),
the per allele odds ratio was higher below the age of 40 years,
although not significantly so. Other studies have found that the
relative risks associated with CHEK2 1100delC and ATM mutations
are somewhat higher at young ages (The CHEK2 Breast Cancer
Case–Control Consortium, 2004; Thompson et al, 2005).
We investigated models that allowed for different polygenic
(modifying) variances for BRCA1 and BRCA2 mutation carriers.
The point estimate of the BRCA1 variance was lower than of the
polygenic variance for noncarriers, while that of the BRCA2
variance was more similar to the latter. This would be consistent
with recent findings that the established breast cancer suscept-
ibility variants at the FGFR2 and MAP3K1 loci are associated with
the risk of breast cancer in BRCA2 but not BRCA1 carriers
(Antoniou et al, in press b). The latter observations may reflect
differences in susceptibility by tumour characteristics, since some
loci confer susceptibility only to ER-positive disease (Garcia-
Closas, in press). However, the power to distinguish between these
models, even with the current large data set, was limited, and we
could not reject a model with equal polygenic and modifying
variances. This would be consistent with the hypothesis that most
‘polygenes’ confer similar relative risks in BRCA1 carriers, BRCA2
carriers and noncarriers.
As part of the model fitting, we have also re-estimated the breast
and ovarian cancer risks in BRCA1 and BRCA2 carriers. The
majority of the current data came from families of unselected
series of cases that had been previously used to estimate the
BRCA1 and BRCA2 penetrance (Antoniou et al, 2003). The present
analyses differed in the following three important respects: they
Table 7 Assumed relative risk parameters for the cancer risks at sites
other than breast and ovary
Relative risk
Site Age group (years) BRCA1 BRCA2
Male breast 8.00
a 80.00
b
Prostate o65 1.82
c 7.33
d
X65 0.84
c 3.39
d
Pancreatic o65 3.10
c 5.54
d
X65 1.54
c 1.61
d
aDF Easton (unpublished data).
bThompson and Easton (2001).
cThompson and
Easton (2002).
dThe Breast Cancer Linkage Consortium (1999).
Birth
Breast
cancer
Contralateral
BC
Ovarian
cancer
Pancreatic
cancer
Death
or end of
follow-up
Figure 5 The extended BOADICEA transition model for female
patients.
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incidences, which vary continuously with age; and, most impor-
tantly, they were estimated while allowing for other residual familial
effects (i.e., polygenic-modifying component). Although a direct
comparison with the breast cancer estimates in the original report is
not strictly valid, the present breast cancer estimates are generally
lower. There is a straightforward explanation for this difference. The
present breast cancer risks (Figures 1–4) represent the risks
averaged over all possible polygenic and modifying effects and
would therefore be applicable to a randomly chosen BRCA1 or
BRCA2 mutation carrier (i.e., for a carrier without any knowledge of
her family history). In contrast, the estimates in Antoniou et al
(2003) represent the breast cancer risks among BRCA1 and BRCA2
mutation carriers who have an affected first-degree relative (affected
with breast cancer in most cases). Under the BOADICEA model,
these women would be expected to have higher than average breast
cancer risks, as demonstrated elsewhere (Antoniou et al, 2004) and
as other researchers have pointed out (Begg, 2002). An important
consequence of these arguments is that there is no single set of
penetrance estimates that applies to all carriers. The range of breast
cancer cumulative risks given by the distribution of the polygenic/
modifying component implies that the cancer risks depend strongly
on the genotypes at modifying loci – not just the presence of a
mutation – and these can be much higher or much lower than the
average estimates. To utilise the full range of these risk estimates
would require the modifying genes to be identified, but, in the
meantime, the results indicate that family history in addition to
mutation status should be taken into account in genetic counselling.
The BOADICEA model allows this level of sophistication. This
feature is also consistent with the recent results of Begg et al (2008),
who also demonstrated that breast cancer risks vary between
families where a BRCA1 or BRCA2 mutation has been identified.
The updated version of BOADICEA was one of the models used in
a recent validation study of BRCA1 and BRCA2 carrier prediction
algorithms (Antoniou et al, in press a) using a large series of families
seen in the UK genetics clinics. The BOADICEA model was
compared against other models including the genetic risk models
BRCAPRO (Parmigiani et al, 1998) and IBIS (Tyrer et al, 2004). It
was found to be the most accurate model in terms of predicting the
observed number of mutations in total, and across the whole range
of probabilities of being a mutation carrier, and had the highest
power to discriminate between mutation carriers and noncarriers.
This, taken together with the observation that BOADICEA also
predicts well the FRRs of breast cancer, provides confidence that
BOADICEA is a well-validated and well-calibrated model that can be
a useful tool for genetic counselling individuals with family history of
breast cancer. However, further validation studies will be important
to evaluate the ability of this (and other) models to predict the
prospective risk of developing breast or ovarian cancer.
The current version of BOADICEA has now been implemented
as a user-friendly Web-based program (http://www.srl.cam.ac.uk/
genepi/boadicea/boadicea_home.html). Users can either create a
pedigree online, or can upload a pedigree file. The program allows
for families of any size or structure; pedigrees built online
are restricted to first- and second-degree relatives but uploaded
files can be of arbitrary complexity. It has been shown that
relatives more distant than second degree can provide important
information for risk models (Antoniou et al, 2005; Barcenas et al,
2006). The BOADICEA returns both predicted probabilities of
carrying a BRCA1 or a BRCA2 mutation, and risks (by the age of
up to 80 years) of developing breast or ovarian cancer for
unaffected individuals, or the risk of contralateral breast cancer or
ovarian cancer for those who have already developed a first breast
cancer. The code has also been modified to allow for the possibility
that the individual is of Ashkenazi Jewish origin. This case requires
separate consideration owing to the high prevalence of three
founder mutations in this population (Satagopan et al, 2001), so
that estimates based on allele frequencies for the United Kingdom
would be misleading. For this purpose, we used the BRCA1 and
BRCA2 mutation prevalence for young controls (BRCA1: 1.6% and
BRCA2: 1.2%) reported in Satagopan et al (2001). The cancer risks
among BRCA1 and BRCA2 mutation carriers, and the polygenic
variance, were assumed to be the same in the Ashkenazi and non-
Ashkenazi versions. Similar modification will be required for other
populations where the frequencies of BRCA1 and BRCA2 muta-
tions are different (e.g., the Icelandic). These will be implemented
at a later stage.
There are several directions in which our model can be
extended, and these may lead to improvements in discriminatory
power and more accurate predictions of cancer risk. Now that
some of the loci that may comprise the ‘polygenic’ component
have been identified, it will be possible to incorporate their specific
effects into the model, allowing these additional loci to be used in
counselling. Other extensions that remain challenges include the
incorporation of variation in risk by mutation type; extensions to
other populations with different risks and/or mutation frequencies;
inclusion of data on pathological subtypes (for example, ‘basal’
breast cancer); tumour histological characteristics; and the
inclusion of hormonal, reproductive and lifestyle risk factors.
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APPENDIX
To obtain BRCA1 and BRCA2 incidences as continuous functions
of age, we fitted models in which the log-relative hazards (G(t))
were piecewise linear functions of age. For example,
GiðtÞ¼a þ b1ðt   20Þ; 20ptp29
¼ a þ 10b1 þ b2ðt   30Þ; 30ptp39
¼ a þ 10ðb1 þ b2Þþb3ðt   40Þ; 40ptp49
¼ a þ 10ðb1 þ b2 þ b3Þþb4ðt   50Þ; 50ptp59
¼ a þ 10ðb1 þ b2 þ b3 þ b4Þþb5ðt   60Þ; 60ptp69
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